Related Experiment Videos
[Clinical evaluation of meropenem in the pediatric field]
K Kawauchi1, M Yokoyama, Y Takahashi
1Department of Pediatrics, School of Medicine, Hirosaki University.
Abstract:
A clinical study on a new carbapenem antibiotic, meropenem (MEPM), was carried out in acute pediatric infections. MEPM was administered to 8 patients including 3 patients with acute pneumonia, 2 with cervical lymphadenitis, 1 with acute tonsillitis, and 1 with cellulitis and 1 with sepsis. The overall efficacy rate was 100%. As an adverse reaction, diarrhea was observed in 1 patient. In clinical laboratory tests 1 patient was found to have S-GPT elevation which normalized after discontinuation of MEPM. MEPM appears to be effective and safe drug for pediatric acute infections.
Insights
Meropenem (MEPM), a new carbapenem antibiotic, showed 100% efficacy in treating acute pediatric infections like pneumonia and sepsis. This study suggests MEPM is a safe and effective treatment option for children.
Area of Science:
- Pediatric Infectious Diseases
- Clinical Pharmacology
- Antibiotic Therapy
Background:
- Acute infections in children require effective and safe antimicrobial agents.
- Carbapenem antibiotics offer broad-spectrum activity against various bacterial pathogens.
Observation:
- A clinical study evaluated meropenem (MEPM) in 8 pediatric patients with acute infections.
- Infections treated included pneumonia, cervical lymphadenitis, tonsillitis, cellulitis, and sepsis.
Findings:
- Meropenem demonstrated a 100% overall efficacy rate across all treated pediatric cases.
- The only adverse events reported were transient diarrhea in one patient and S-GPT elevation in another, which normalized post-treatment.
Implications:
- Meropenem presents a promising therapeutic option for managing severe acute pediatric infections.
- Further research may establish meropenem as a key antibiotic in pediatric infectious disease management.